Roflumilast Efficacy and Safety in Pediatric AD

Panelists discuss how recent research has evaluated nonsteroidal topical agents for mild to moderate pediatric atopic dermatitis (AD), showing encouraging results for safety, tolerability, and durability. These findings suggest that effective inflammation control can be achieved with minimal irritation or adverse effects.

They highlight the importance of meaningful measures—such as itch reduction, body surface area improvement, and quality-of-life scores—to guide treatment decisions. These patient-centered outcomes help clinicians tailor therapies to what matters most for families.

Panelists emphasize that as research continues, these data-driven insights will refine treatment approaches and support individualized care for every child.